Early evidence now shows that forgoing RhD immune globulin (RhIG) in most pregnancies under 12 weeks does not raise the risk of hemolytic disease of the fetus and newborn (HDFN), according to a review published recently in F&S Reports.
This shift directly affects patients experiencing early pregnancy loss after fertility treatment by simplifying care, minimizing additional clinic visits and helping reduce stress during an already painful experience.
Early pregnancy loss is common in fertility care and often arrives without warning. Patients not only face grief but also must navigate decisions about management and whether they need RhIG.
Until recently, many clinicians routinely administered RhIG to RhD-negative patients even with light bleeding, despite uncertain benefit in very early gestation. The drug comes from donated human plasma, and shortages are frequent, making accurate and consistent use especially important.
RhIG works by preventing the body from forming antibodies against fetal red cells that carry the RhD antigen. Those antibodies can cause HDFN in later pregnancies. Although primitive blood formation begins around 4 weeks, fetal red cells generally do not display RhD antigens until about 6 weeks.
“Considering the very low risk of alloimmunization at least than 12 weeks of gestation, our specialty should put forth recommendations to forgo routine RhIG prophylaxis for early pregnancy loss,” explained this review’s authors.
Read more about treatment and care for HDFN
To trigger immunity, enough fetal cells must enter the maternal bloodstream, something most likely at delivery rather than at early gestations. Studies show that before 12 weeks, fetal blood exposure is extremely small and unlikely to lead to sensitization.
Professional recommendations have changed over time. In 2017, the American College of Obstetricians and Gynecologists said evidence was insufficient to support RhIG for threatened loss before 12 weeks, yet many clinicians continued giving it broadly.
The Society of Family Planning later concluded that skipping RhIG before 12 weeks was very unlikely to increase risk, though it still advised a 50 μg/250 IU dose for ectopic pregnancies, sharp curettage or other invasive procedures. The Society for Maternal-Fetal Medicine continued to recommend offering RhIG when feasible. In December 2024, the American College of Obstetricians and Gynecologists issued a Clinical Practice Update recommending forgoing routine Rh testing and RhIG before 12 weeks.
International data reinforce these changes. Countries that do not give RhIG early show no higher rates of Rh antibodies compared with countries that administer it at any gestational age. Laboratory studies of patients undergoing aspiration abortion under 12 weeks also reveal minimal fetal red cell transfer.
For patients, clearer and more unified national guidelines could reduce unnecessary injections, lessen emotional and logistical burdens and preserve a limited medication without compromising safety.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
